CTMX CytomX Therapeutics, Inc.: Enterprise Value-to-Revenue Multiple

cytomx.com (CTMX) - corporate logo

CytomX Therapeutics (CTMX) relies on outsourcing for production and testing to maintain the flexibility of its scientific team. Risks are linked to raw material supply chain disruptions, although the sector remains a defensive asset regardless of macroeconomic conditions. Current EV/Sales dynamics on GURU.Markets indicate that quotes are overheated relative to sales, while the value of 7298.65 serves as a current indicator signaling a probable valuation correction.

CytomX Therapeutics - CTMX Enterprise Value-to-Revenue Ratio (period 11/23/2025 - 11/20/2026)

CytomX Corp - analytical breakdowns and key metrics (CTMX)

- stock quotes and analyst forecast:
- company stock capitalization data:
Fundamental valuation:CTMX, CytomX Therapeutics, Inc.
Original product of CytomX Therapeutics Inc

This indicator reflects the enterprise value minus net debt relative to sales volume. The metric identifies unjustified market optimism when valuation outpaces actual financial results. By analyzing the trajectory of the company's value-to-revenue ratio, an investor can identify the risk of a sharp correction should market conditions shift. This is critical for CytomX Therapeutics (CTMX), as its capitalization is sustained by expectations surrounding the Probody platform. Any negative developments in partner research would instantaneously collapse the inflated multiple.